IPOPI’s 2022 Review of Activities and Achievements
2022 was a very special year for IPOPI, as we celebrated our 30th anniversary as an organisation! We had the pleasure of celebrating this milestone at the Global Patients’ Meeting in Gothenburg, Sweden, together with over 100 patient advocates from 34 countries. During this festivity, we seized the opportunity to appreciate current and successive Board and Staff members, who all have played an integral role in shaping IPOPI’s journey. As an organisation, we are proud to work with and represent a growing number of national member organisations who all share our common vision to improve the lives of these patients with primary immunodeficiencies (PIDs).
2022 Highlights: A strong educational programme
In 2022, IPOPI organised various events and engaged in campaigns and policy efforts to improve care for patients with PIDs. Aligned with our strategic plan for 2021-2025, we remained steadfast in delivering a robust educational programme that empowers both patient advocates and healthcare professionals alike. A notable example is the 5th International Primary Immunodeficiency Congress (IPIC), which took place in Vilamoura, Portugal, in April 2022. This congress brought together 600 delegates interested in the diagnosis and clinical care of primary immunodeficiencies (PID), an outstanding achievement!
Throughout the year, we have also released a motion design video series covering primary immunodeficiency diagnosis and treatment, and published six new educational PID leaflets. In addition to this, we organised several EU PID Forums in the European Parliament, as well as a successful Asian regional meeting in Kuala Lumpur (Malaysia), a well-attended national meeting in Bangkok (Thailand), and of course, our Global Patients’ Meeting, organised back to back with the ESID congress.
We have continued our support for stakeholder cooperation in initiatives like Screen4Rare and ERN-Rita and started new collaborations with organisations such as United Nations Institute for Training and Research (UNITAR) and European Alliance for Transformative Therapies (TRANSFORM), among others.
We hope you will enjoy reading this annual report and exploring the most significant IPOPI initiatives, campaigns, and events in the previous year.
Explore the annual review